Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jan 20;84(3):265-72.
doi: 10.1212/WNL.0000000000001168. Epub 2014 Dec 10.

Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication

Affiliations
Randomized Controlled Trial

Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication

John D Markman et al. Neurology. .

Abstract

Objectives: To test the effects of pregabalin on the induction of neurogenic claudication.

Methods: This study was a randomized, double-blind, active placebo-controlled, 2-period, crossover trial. Twenty-nine subjects were randomized to receive pregabalin followed by active placebo (i.e., diphenhydramine) or active placebo followed by pregabalin. Each treatment period lasted 10 days, including a 2-step titration. Periods were separated by a 10-day washout period, including a 3-day taper phase after the first period. The primary outcome variable was the time to first moderate pain symptom (Numeric Rating Scale score ≥4) during a 15-minute treadmill test (Tfirst). Secondary outcome measures included pain intensity at rest, pain intensity at the end of the treadmill test, distance walked, and validated self-report measures of pain and functional limitation including the Roland-Morris Disability Questionnaire, modified Brief Pain Inventory-Short Form, Oswestry Disability Index, and Swiss Spinal Stenosis Questionnaire.

Results: No significant difference was found between pregabalin and active placebo for the time to first moderate pain symptom (difference in median Tfirst = -1.08 [95% confidence interval -2.25 to 0.08], p = 0.61). In addition, none of the secondary outcome measures of pain or functional limitation were significantly improved by pregabalin compared with active placebo.

Conclusions: Pregabalin was not more effective than active placebo in reducing painful symptoms or functional limitations in patients with neurogenic claudication associated with lumbar spinal stenosis.

Classification of evidence: This study provides Class I evidence that for patients with neurogenic claudication, compared with diphenhydramine, pregabalin does not increase the time to moderate pain during a treadmill test.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow of trial participants
Bid = twice a day; LSS = lumbar spinal stenosis.
Figure 2
Figure 2. Distribution of time to walking-induced moderate pain severity (≥4 on 0–10 NRS) by treatment condition
NRS = Numeric Rating Scale.

Similar articles

Cited by

References

    1. Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical versus nonsurgical therapy for lumbar spinal stenosis. N Engl J Med 2008;358:794–810. - PMC - PubMed
    1. Porter RW. Spinal stenosis and neurogenic claudication. Spine 1996;21:2046–2052. - PubMed
    1. Ciol MA, Deyo RA, Howell E, Kreif S. An assessment of surgery for spinal stenosis: time trends, geographic variations, complications, and reoperations. J Am Geriatr Soc 1996;44:285–290. - PubMed
    1. Comer CM, Redmond AC, Bird HA, Conaghan PG. Assessment and management of neurogenic claudication associated with lumbar spinal stenosis in a UK primary care musculoskeletal service: a survey of current practice among physiotherapists. BMC Musculoskelet Disord 2009;10:121. - PMC - PubMed
    1. Onel D, Sari H, Donmez C. Lumbar spinal stenosis: clinical/radiologic therapeutic evaluation in 145 patients—conservative treatment or surgical intervention? Spine 1993;18:291–298. - PubMed

Publication types

MeSH terms